Toggle Menu

Press Room

Major Annoucement on Kidney Cancer Vaccine


Roswell Park Launches Landmark Immunotherapy Vaccine Trial [Read More]

The ability to stretch out the attack for a long-term, durable response suggests that the vaccine may be effective in preventing disease recurrence. The new NY-ESO-1 dendritic cell vaccine is expected to show great promise in patients with bladder, brain, breast, esophageal, gastrointestinal, hepatocellular, kidney, lung, melanoma, ovarian, prostate, sarcoma and uterine tumors.

NeonCRM by Neon One